Replies to post #8685 on Halozyme Therapeutics Inc (HALO)

[maumar]

Interesting. I wonder when this and Alteogen's will get approved. It's certainly odd that they have been able to develop a "standalone" before Halo's patents expire. In any case, this is one of the reasons Halo should not rely just on Enhanze and get serious on M&A imo.

"HLB3-002 is a standalone of Halozyme's rHuPH20 (Original) and has the same amino acid sequence."